Aim higher with Ascend

Let’s work together to build the future of advanced therapies!

Let’s Talk

Since late 2024, we have been aligned with ABL, Inc. Together we offer scalable support for specialty advanced therapeutic developers from research to commercialization with United States and European locations.

Learn More

Ascend can support your journey at any scale for:

Gene therapies

Immunotherapies

Oncolytics

Vaccines

Gene therapies

Immunotherapies

Oncolytics

Vaccines

Development Based Expertise

All our work comes from a background of developing therapies. When we struggled to find our own CDMOs, we became one. Discover the difference of working with a team with deep chemistry, manufacturing & controls (CMC).

Learn More

Decades of Biologics, Innovation & Expertise

60+ years custom biologics & vaccines support with 20+ AAV development expertise

Next gen technologies & analytics complemented by deep regulatory acumen

Onsite fill-finish capabilities in multiple US locations

60+ years custom biologics & vaccines support with 20+ AAV development expertise

Next gen technologies & analytics complemented by deep regulatory acumen

Onsite fill-finish capabilities in multiple US locations

Latest News & Insights

News

5 March 2025

Ascend Advanced Therapies Appoints John Chiminski as Chair & Karen Flynn as Independent Director

Rockville, MD – March 5, 2025 – Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner,...

Blogs

3 February 2025

Polo-like kinase inhibitors increase AAV production by halting cell cycle progression

Recombinant adeno-associated viruses (rAAVs) are commonly used in gene therapy for preclinical research and therapeutic applications. Despite the clinical...

Blogs